Market Currents
Merck (MRK) signs a deal to use GE Healthcare's (GE) Flutemetamol imaging agent in clinical...
-
Tuesday, December 18, 2012, 8:39 AM ETMerck (MRK) signs a deal to use GE Healthcare's (GE) Flutemetamol imaging agent in clinical studies of Merck's MK-8931 drug for treating Alzheimer's disease. Flutemetamol, which performed well in its own Phase III trials, helps detect beta amyloid deposits in the brain. The build-up of beta amyloid has been associated with Alzheimer's. (PR)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
